Healthcare Services

Technological advancements in Alzheimer’s diagnostics with improved accuracy are shaping the Alzheimer’s diagnostics market

April 17, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Alzheimer’s Disease Diagnostic Market From 2026 To 2030?

The alzheimer’s disease diagnostic market has experienced substantial expansion in recent years. It is anticipated to grow from $7.26 billion in 2025 to $8.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The historical increase in this market can be ascribed to the rising occurrence of alzheimer’s disease, heightened understanding of neurodegenerative conditions, the use of MRI and PET imaging, the proliferation of diagnostic centers and hospitals, and financial contributions to cognitive assessment research.

The alzheimer’s disease diagnostic market size is poised for significant expansion over the next few years. It is expected to reach $11.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.3%. This anticipated growth is fueled by the development of innovative biomarkers and imaging tracers, the incorporation of AI for earlier detection, increasing government and private funding directed towards Alzheimer’s research, the spread of personalized medicine initiatives, and a rise in multi-center clinical trials. Prominent trends expected during this forecast period include a greater embrace of biomarker-based diagnostics, an increasing application of neuroimaging techniques for early identification, an uptick in cognitive assessment testing, the broadened availability of genetic testing for Alzheimer’s risk evaluation, and the integration of multi-modal diagnostic strategies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Leading Drivers Are Supporting The Alzheimer’s Disease Diagnostic Market Expansion?

The anticipated expansion of the Alzheimer’s disease diagnostic market is attributed to the rising incidence of chronic diseases. Conditions like cardiovascular disease, diabetes, and hypertension are deeply linked to a heightened risk of Alzheimer’s and other forms of dementia, thereby boosting the need for timely and precise diagnostic tools. A primary contributor to this surge in chronic diseases is the global increase in sedentary habits, with extensive research consistently demonstrating considerably higher rates of conditions like diabetes and cardiovascular disease among those with inactive lifestyles. Alzheimer’s diagnostics aid healthcare systems by facilitating early detection, allowing for prompt interventions, and assisting in patient management to retard the advancement of the disease. For example, data from November 2023, provided by Heritage Health Services, a US-based nonprofit healthcare research organization, indicated that 6.7 million Americans aged 65 or above were affected by Alzheimer’s dementia. The prevalence escalated with age: 5.0% for 65–74 years, 13.1% for 75–84 years, and 33.3% for 85+ years. Projections show this figure reaching almost 13 million by 2050. Consequently, the escalating prevalence of chronic disease is fueling the expansion of the Alzheimer’s disease diagnostic market.

How Is The Alzheimer’s Disease Diagnostic Market Categorized Across Its Segment Groups?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

What Emerging Trends Are Seen In The Alzheimer’s Disease Diagnostic Market?

Leading companies in the Alzheimer’s disease diagnostic market are concentrating on enhancing blood-based biomarker tests, a development expected to streamline the diagnostic process for Alzheimer’s disease. This approach aims to lessen dependence on more invasive procedures and improve patients’ access to timely treatment. For example, in October 2023, Quanterix, a US-based biotechnology research company, introduced the LucentAD p-Tau 217 test, which serves as a biomarker for Alzheimer’s pathology, demonstrating clinical sensitivity and specificity in blood. Traditional methods for cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are often expensive, invasive, and not broadly accessible. Additionally, the LucentAD p-Tau 217 test integrates Quanterix’s ultra-sensitive SimoaÒ technology with J&J Innovative Medicine’s thoroughly tested p-Tau 217 antibodies, ensuring remarkable accuracy and a simpler procedure.

Which Firms Are Influencing Competition In The Alzheimer’s Disease Diagnostic Market?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Get The Full Alzheimer’s Disease Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Which Geographic Region Dominates The Alzheimer’s Disease Diagnostic Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Alzheimer’s Disease Diagnostic Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2026, By The Business Research Company

Autism Spectrum Disorder Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/autism-spectrum-disorder-diagnostics-global-market-report

Alzheimers Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

Neurological Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795